65,437 trials
Chronic Total Occlusion
Primary: Composite Rate of Major Adverse Events — 3.3 percentage of participants
Drug Safety
Primary: Subjects Experiencing Discomfort When Undergoing Peripheral Arteriography — 53; 92; 48; 82 participants
Alveolar Bone Loss
Primary: Bone Regeneration — 79; 63 % bone height
Pain
Primary: Pain Rating — 7.36; 5.61; 7.54; 6.75 units on a scale — p=<0.001
Gastroesophageal Reflux Disease
Primary: Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8 — 36.96; 43.01; 44.37; 38.79 percentage of days — p=0.128
Melanoma
Primary: Number of Participants With On-study Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related AEs, Immune-related AEs (irAEs)…
CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Primary: Peak Plasma Concentration (Cmax) of 2% Diltiazem — 0.340; 0.624 ng / mL
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
Small Bowel Visualization
Primary: Number of Patients With Persistent or Recurrent Bleeding — 16 participants
Female Sexual Arousal Disorder · Hypoactive Sexual Desire Disorder
Primary: The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE) — 0.2; 0.6; 0.7; 0.8 SSEs — p=<0.05
Cervical Ripening · Induction of Labor
Primary: Time of Maximum Plasma Concentration (Tmax) of Misoprostol After Insertion — 4 hours
Hyperparathyroidism, Secondary · Kidney Failure, Chronic
Primary: Change in Endothelial Cell Function — .23 percent change in FMD
Primary Erythromelalgia · Inherited Erythromelalgia
Primary: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 — 0.24; 2.4 cooling uses/day
Chronic Wounds
Primary: Change in Bacterial Counts — 4460; -1030000 cfu/mL
Renal Cell Carcinoma · Kidney Cancer
Primary: Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT. — 0.76; 0.86; 0.86; 0.47 Proportion of participants — p=0.023